RPG Life Sciences has moved quickly to expand its active pharmaceutical ingredient (API) business, spending ₹215 crore on two acquisitions in five weeks and signalling that larger purchases could follow. The company has more than ₹500 crore available for acquisitions, manufacturing expansion, product development and regulatory access. The immediate corporate announcement is significant not only because of the money involved, but because it shows how pharmaceutical companies are trying to build scale by combining facilities, products, customers and approvals rather than adding isolated manufacturing capacity.
The strategy also brings an industrial-infrastructure question into focus. Pharmaceutical manufacturing depends on specialised plants, regulatory-compliant production systems, research and development capabilities, skilled employees and access to export markets. RPG Life Sciences’ acquisitions are intended to assemble these elements into a larger API platform. Whether the strategy delivers will depend less on the number of assets acquired than on how effectively the company integrates them and fills capacity that is currently underused.
The company’s latest transaction was agreed last week, when RPG Active Pharma, a wholly owned subsidiary of RPG Life Sciences, agreed to acquire the API and intermediates business of Raghava Life Sciences for up to ₹135 crore. That followed the July 29 acquisition of Actis Generics for ₹80 crore. RPG has described the approach as a “buy-and-build” strategy aimed at creating a scaled and integrated API business.
According to Managing Director Ashok Nair, the company is actively evaluating further opportunities. He said the timing of additional deals would depend on strategic fit, valuation, integration readiness and returns rather than on a predetermined acquisition count. The company is particularly interested in businesses that can add differentiated chemistry, regulatory access and export capabilities.
That approach distinguishes RPG’s expansion from a straightforward capacity-acquisition exercise. The company is not presenting a plant approval or installed capacity figure as sufficient by itself. Nair said a potential US Food and Drug Administration-approved facility would not be acquired merely for the approval. Chemistry, product mix, customers, utilisation potential and economics would also need to be compelling.
The distinction matters because pharmaceutical manufacturing assets can carry substantial fixed costs even when they are not operating at full capacity. Acquiring an underused facility can provide a relatively quick route to scale, but it also creates the responsibility of finding customers, developing products and meeting regulatory requirements. RPG’s plan therefore links physical infrastructure with commercial integration and market access.
The two acquisitions have already changed the reported scale of RPG Active Pharma. Manufacturing capacity has increased from 110 kilolitres to 505 kilolitres. The product portfolio has expanded from 14 products to 45, while the customer base has grown from 123 to more than 250. Employee strength has risen from 217 to over 500, and the research and development pipeline has increased from 12 products to 28, according to Nair.
Raghava contributes about 300 kilolitres of installed capacity at its facility near Hyderabad. The plant has EU-GMP and WHO-GMP approvals, while the business has regulatory credentials that include a Certificate of Suitability to the European Pharmacopoeia, EU Written Confirmation and Korea Drug Master File approvals. These approvals are part of the asset’s value because they can support access to regulated markets, although their commercial value will depend on the products, customers and volumes attached to them.
The available revenue figures also show the gap between installed capacity and current utilisation. Actis and Raghava together generated about ₹70 crore in FY26 revenue. RPG believes the Raghava facility could support approximately ₹200 crore of annual revenue at fuller utilisation without significant incremental capital expenditure. The company intends to pursue that opportunity through new customers, geographic expansion and integration with Actis and its existing API operations.
This makes utilisation the central test of the acquisition strategy. The company has increased capacity nearly fivefold, but the revenue base added by the two acquired businesses remains considerably smaller than the potential it identifies for the Raghava facility alone. The difference is not necessarily evidence of weak assets; it indicates that the next phase of the plan depends on converting infrastructure into recurring production and sales.
The proposed growth model is also broader than supplying RPG Life Sciences’ own formulations business. RPG Active Pharma is being developed primarily as an independent merchant API and advanced-intermediates business. Third-party customers, exports and selected contract development and manufacturing organisation opportunities are expected to form the larger growth opportunity, according to Nair.
That positioning places RPG within a wider effort by global drugmakers to diversify pharmaceutical supply chains and reduce excessive dependence on China. The company’s stated export strategy, however, is not limited to the United States. Its interest in European and Korean regulatory credentials suggests a broader market-access approach, while the company continues to view USFDA-approved manufacturing capability as a longer-term objective rather than an acquisition criterion on its own.
For industrial locations such as Hyderabad, the strategy illustrates how pharmaceutical infrastructure can support more than production capacity. A manufacturing plant is connected to regulatory systems, technical employment, research activity, logistics, customer relationships and export channels. The acquisition has increased RPG’s employee strength by more than two times across the expanded business, while its product and research pipeline has also grown. Those changes show that the physical asset is being integrated with organisational and knowledge capabilities.
At the same time, the supplied information does not establish how quickly the company can reach fuller utilisation, what proportion of revenue will come from exports or how much additional investment will be required for product development and regulatory expansion. It also does not disclose the valuation framework for future acquisitions, the profitability of the acquired operations or the implementation timetable for integrating the businesses. Those remain important variables in assessing whether the buy-and-build model can generate returns.
RPG’s debt-free position provides it with financial flexibility, according to the company’s account. More than ₹500 crore is available for further acquisitions and other uses, but the company has not committed to a fixed number of transactions. That restraint is relevant because rapid consolidation can create integration risks if facilities, product portfolios, regulatory systems and customer relationships do not fit together operationally.
The strategy therefore rests on three linked requirements. First, RPG must select assets with differentiated chemistry and credible regulatory access. Second, it must use the acquired infrastructure more intensively by adding customers and products. Third, it must operate the API platform as a sufficiently independent merchant business rather than relying primarily on internal demand from its formulations operations.
The evidence so far confirms a rapid increase in capacity, products, customers, employees and research activity. It also confirms that the company has identified underutilised infrastructure as the immediate source of potential growth. What remains uncertain is whether that capacity can be converted into the projected revenue scale without substantial additional capital or prolonged integration work.
The next developments to monitor are RPG Life Sciences’ decisions on larger API assets, the pace at which the Raghava facility’s utilisation rises, the integration of Actis and Raghava, and the expansion of third-party and export customers. These milestones will indicate whether the company’s acquisitions have created a scalable manufacturing platform or simply a larger collection of pharmaceutical assets.
